Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewA 1070722 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor (Ki = 0.6 nM for GSK-3α and GSK-3β). Displays high selectivity (> 50-fold) for GSK-3 over a panel of other kinases tested, including CDK family members. Decreases phosphorylation of microtubule-associated protein Tau in vitro; protects rat primary cortical neurons against β amyloid and glutamate challenge. Brain penetrant.
A 1070722 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Kinase Inhibitor Library. Find out more about compound libraries available from Tocris.
M. Wt | 362.31 |
Formula | C17H13F3N4O2 |
Storage | Store at RT |
Purity | ≥99% (HPLC) |
CAS Number | 1384424-80-9 |
PubChem ID | 49830684 |
InChI Key | VQPBIJGXSXEOCU-UHFFFAOYSA-N |
Smiles | O=C(NC3=NC(C(F)(F)F)=CC=C3)NC2=CC=NC1=CC(OC)=CC=C12 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 36.23 | 100 |
The following data is based on the product molecular weight 362.31. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.76 mL | 13.8 mL | 27.6 mL |
5 mM | 0.55 mL | 2.76 mL | 5.52 mL |
10 mM | 0.28 mL | 1.38 mL | 2.76 mL |
50 mM | 0.06 mL | 0.28 mL | 0.55 mL |
References are publications that support the biological activity of the product.
Bakker et al (2011) A-1070722, a potent, selective, and centrally active glycogen synthase kinase-3 (GSK-3) inhibitor for the treatment of psychiatric and neurodegenerative disorders. Society for Neuroscience (Abstract) 568
If you know of a relevant reference for A 1070722, please let us know.
Keywords: A 1070722, A 1070722 supplier, A1070722, glycogen, synthase, kinases, 3, inhibits, inhibitors, potent, selective, brain, penetrant, neuroprotective, tau, phosphorylation, beta, b, amyloid, Glycogen, Synthase, Kinase, 4431, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for A 1070722. Do you know of a great paper that uses A 1070722 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review A 1070722 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.